Clinical trials: Human Cancers
Partial Nephrectomy, Kidney Cancer
Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy
After partial nephrectomy, kidney function decreases by about 10% overall and by about 20% in the operated kidney. This is primarily due to the loss of healthy parenchymal volume during resection of the tumor.
- Conditions
- Partial Nephrectomy, Kidney Cancer, Renal Function Aggravated
- Trial name
- NCT03323021
- Testing
- Dehydrated human amnion/chorion membrane, Standard of Care
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- MiMedx Group, Inc.
Melanoma
A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
The purpose of this study is to evaluate the safety and effectiveness of the intetumumab, alone and in combination with dacarbazine, in patients with stage 4 melanoma.
- Trial name
- NCT00246012
- Testing
- Intetumumab, Dacarbazine
- Where
- 32 sites in United States, Germany and 1 more
- Volunteers
- 144 people
- Sponsor
- Centocor, Inc.
Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
This Phase1, multicenter, first-in-human, open-label, dose-escalation, and dose expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX35 administered as a single-agent…
- Trial name
- NCT05360381
- Testing
- HLX35
- Where
- 2 sites in China
- Volunteers
- 82 people
- Sponsor
- Shanghai Henlius Biotech
Infections, Papillomavirus
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00456807
- Testing
- Cervarix TM
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Breast Cancer, Anemia
Treatment for Patients Suffering From Anemia Due to Chemotherapy
The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in female breast cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia…
- Trial name
- NCT00120692
- Testing
- Darbepoetin Alfa, Recombinant Human Erythropoietin
- Sponsor
- Amgen
Breast Neoplasms, Solid Tumors
A Phase 1/2a Study of K-1728 in Advanced Solid Tumors
This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors.
- Conditions
- Breast Neoplasms, Solid Tumors, PIK3CA Gene Mutation
- Trial name
- PIKYMA-01 (NCT07861932)
- Testing
- K-1728, Fulvestrant, Palbociclib
- Volunteers
- 110 people
- Sponsor
- KymaThera, Inc.
Breast Neoplasms
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line…
- Trial name
- PERUSE (NCT01572038)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 299 sites in Algeria, Argentina and 37 more
- Volunteers
- 1,436 people
- Sponsor
- Hoffmann-La Roche
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
This extension study aims to evaluate the long-term protection and immune response of the bivalent HPV vaccine in women aged 18-30 who participated in a previous efficacy study (311-HPV-1003).
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN - Cervical Intraepithelial Neoplasia
- Trial name
- NCT06776055
- Testing
- HPV-16/18 vaccine
- Where
- 9 sites in China
- Volunteers
- 5,372 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Advanced Solid Tumor, Metastatic Cancer
FIH XON7 in Advanced/Metastatic Solid Tumors
This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to…
- Trial name
- FIPO23 (NCT06154291)
- Testing
- XON7
- Where
- 5 sites in Belgium, France
- Volunteers
- 255 people
- Sponsor
- Xenothera SAS
Advanced Solid Tumor
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.
- Trial name
- NCT06992713
- Testing
- H1710 for Injection
- Where
- 4 sites in China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Breast Cancer
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
This is an Asia-Pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-naïve…
- Trial name
- PEONY (NCT02586025)
- Testing
- FEC Chemotherapy, Surgery, Docetaxel
- Where
- 23 sites in China, South Korea and 2 more
- Volunteers
- 329 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Advanced Solid Tumor, Hepatocellular Carcinoma
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.
- Trial name
- NCT06005740
- Testing
- TORL-4-500
- Where
- 10 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Trial name
- ELUCIDATE (NCT05985655)
- Testing
- GTAEXS617, SoC
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 230 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Neoplasms by Site
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20. This study will include participants with 1 of the following advanced or metastatic tumors approved for…
- Trial name
- NCT03656718
- Testing
- nivolumab, rHuPH20
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 139 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer
This is a Phase I, open-label, first time in human study of GSK923295, in adult subjects with cancers that do not respond to standard therapy.
- Trial name
- NCT00504790
- Testing
- GSK923295
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Advanced Cancer
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of this study is to determine whether BMS-986258 both monotherapy and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors.
- Trial name
- NCT03446040
- Testing
- BMS-986258, Nivolumab, rHuPH20
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
The purpose of this study is to test if the BG-92505 is safe and if it works in patients with advanced solid tumors when it is given on its own or in combination with anti-cancer agents.
- Trial name
- NCT07896460
- Testing
- BG-92505, Anti-Cancer Agent
- Volunteers
- 137 people
- Sponsor
- BeOne Medicines
Renal Cell Carcinoma, Non-small Cell Lung Cancer
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing…
- Conditions
- Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT05769959
- Testing
- RO7515629, tocilizumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of…
- Trial name
- NCT07438782
- Testing
- GSK5533524
- Where
- 20 sites in United States, Canada and 6 more
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.